News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

A lead plaintiff acts on behalf of all other class members in directing the Regeneron class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Regeneron class ...

Currently, Regeneron Pharmaceuticals is a Zacks Rank ... as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0 ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... activity and easier YoY comparisons. Furthermore, all 11 S&P 500 sectors are expected to see positive EPS ...

Regeneron Pharmaceuticals discovers ... Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more.

All data is as of the close of the day on Friday ... beating its benchmark by 150 percentage points (see more details here). Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is an American ...

On Wednesday, January 22, stocks finished higher as all 3 of the major indexes ended ... by 150 percentage points (see more details here). Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is an ...